Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study
DiscussionThe results of this study could influence the therapy of patients with COVID-19 and affect the course of the disease worldwide, as infliximab is globally available and approved by several international drug agencies.Trial registrationThe trial was registered atclinicaltrials.gov (NCT04922827, 11 June 2021) and at EudraCT (2021-002098-25, 19 May 2021). (Source: Trials)
Source: Trials - September 2, 2022 Category: Research Source Type: clinical trials
CT to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis
Condition: Ulcerative Colitis Intervention: Device: Adacolumn Sponsors: Adacyte Therapeutics SL; Adknoma Health Research Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 24, 2022 Category: Research Source Type: clinical trials
